Drug Approval | January 13, 2025
USFDA classifies Biocon Biologics Johor Bahru site, Malaysia as VAI
Biocon Biologics remains committed to global standards of quality and compliance
Biocon Biologics remains committed to global standards of quality and compliance
Modi remarked that more than 20 illustrious research institutions such as IISc, IITs, CSIR and DBT-BRIC have played a major role in this research
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
The transaction is part of a broader agreement with Bureau Veritas covering its worldwide food laboratory testing activities
The site’s GMP Certification has been successfully renewed
The project is set to attract significant manufacturing investments of approximately Rs. 10,500 crore and is also projected to create around 1 lakh direct and indirect jobs
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
Services like 24/7 Ayush Multi-OPD clinics, mobile healthcare units, free distribution of Ayush medicines, and yoga camps are there for all visitors
He also laid the foundation stone for a state-of-the-art 50-bedded Critical Care Block (CCB)
Subscribe To Our Newsletter & Stay Updated
